Analyst Price Target is $6.00
▲ +590.45% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Mainz Biomed in the last 3 months. The average price target is $6.00, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 590.45% upside from the last price of $0.87.
Current Consensus is
Moderate Buy
The current consensus among 2 contributing investment analysts is to moderate buy stock in Mainz Biomed. This Moderate Buy consensus rating has held steady for over two years.
Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.
Read More